Warnings
Cocaine (4%); Caffeine (39%); Levamisole (18%); Lidocaine (13%); Unknown (26%) Mistenni: Kokaina. Rilevat Kokaina 4%, Kaffeina 39%, Levamisole 18%, Lidokajna 13%, Unknown 26%. Lokazzjoni: Marseille, Franza. Data: 2026-07-09. Sors: druglab.fr.
Pillola Cocaine (4%); Caffeine (39%); Levamisole (18%); Lidocaine (13%); Unknown (26%) — Marseille, Franza — 2026-07-09
Detected Cocaine 4%, Caffeine 39%, Levamisole 18%, Lidocaine 13%, Unknown 26%
Expected Cocaine
Logo Unknown
Color white
Location Marseille, France
Date 2026-07-09
Source druglab.fr
Media No image Detected Substances Cocaine 4% Caffeine 39% Levamisole 18% Lidocaine 13% Unknown 26% Expected vs Detected Cocaine
Detected result: Cocaine 4%, Caffeine 39%, Levamisole 18%, Lidocaine 13%, Unknown 26%
Sample Details No additional sample descriptors available.
Testing Context Location: Marseille, Franza Date tested: 2026-07-09 Source: druglab.fr Harm Reduction Similar-looking pills can contain different substances or strengths. Use drug checking services when available. Start low and avoid assuming a logo identifies the contents. SampleDNA Beta 7237 avviżi relatati · Tgħallem aktar dwar l-impuritajiet komuni.
Cocaine 4% Caffeine 39% Levamisole 18% Lidocaine 13% Unknown 26% Kampjuni relatati u kombinazzjonijiet
Caffeine + Cocaine + Levamisole + Lidocaine + Phenacetin
3 kampjuni
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
Caffeine + Cocaine + Levamisole + Lidocaine
2 kampjuni
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
Amphetamine + Caffeine + Cocaine + Levamisole + Unknown
1 kampjun
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
Benzocaine + Caffeine + Cocaine + Levamisole + Lidocaine
1 kampjun
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
Benzoylecgonine + Caffeine + Cocaine + Ketamine + Lidocaine + Tetramisole + Unknown
1 kampjun
Misjuba flimkien f'riżultati relatati tal-iċċekkjar tad-drogi.
Esploratur SampleDNA
Links This static page is intended as the readable export baseline for crawler and low-capability delivery.